Therapeutic result of the use of HeberFERON® in patients with basal cell carcinoma in the face region

Authors

Abstract

Introduction: the introduction of HeberFERON® in the Cuban drug table as a therapeutic option for basal carcinoma is due to the successful and safe results of its use in any of its subtypes, sizes and locations. This avoids mutilations in the affected area.

Objective: to describe the therapeutic result of the use of intradermal perilesional HeberFERON® in the first patients with basal cell carcinoma in the facial region.

Methods: a descriptive cross-sectional study was carried out at the South Ciego de Ávila Community Polyclinic on the first 10 patients treated with the drug during 2018. The diagnosis of basal cell carcinoma was made based on clinical and histological criteria. The data were collected from the medical records of the patients. Ethical principles were met.

Results: all the patients had white skin (100,00 %). Skin phototype II (60,00 %), male sex (60,00  %), ages between 50 and 59 years (40,00 %), solid histological type (40,00 %), localization anatomical in the inner canthus of the eye (40,00 %) and the favorable response to complete treatment (80,00 %) predominated. Most of the adverse events were mild.

Conclusions: in eight of the first 10 patients treated, the favorable response to treatment was complete

Downloads

Download data is not yet available.

Author Biography

Yadaris Matos Pelegrin, Policlínico Sur Ciego de Avila

Licenciada en Enfermería

Downloads

Published

2020-12-01

How to Cite

1.
del Río Ysla MB, Abreu Rivero Y, Matos Pelegrin Y, Díaz García R. Therapeutic result of the use of HeberFERON® in patients with basal cell carcinoma in the face region. Mediciego [Internet]. 2020 Dec. 1 [cited 2025 Dec. 6];26(4):e2056. Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/2056

Issue

Vol. 26 No. 4 (2020)

Section

Original article

License

Copyright (c) 2021 Maily Bárbara del Río Ysla

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.

The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.